Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study

Paul A. Hamlin, Ian W. Flinn, Nina Wagner-Johnston, Jan A. Burger, Greg P. Coffey, Pamela B. Conley, Glenn Michelson, Janet M. Leeds, Kenneth Der, Yvonne Kim, Alice Sabalvaro-Torres, Matt Birrell, Anjali Pandey, John T. Curnutte, Manish R. Patel

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)E90-E93
JournalAmerican journal of hematology
Volume94
Issue number4
DOIs
StatePublished - Apr 2019
Externally publishedYes

ASJC Scopus subject areas

  • Hematology

Cite this